Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2018

Open Access 01-12-2018 | Research article

Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model

Authors: I. Idigoras, A. Arrospide, I. Portillo, E. Arana-Arri, L. Martínez-Indart, J. Mar, H. J. de Koning, R. Lastra, M. Soto-Gordoa, M. van der Meulen, I. Lansdorp-Vogelaar

Published in: BMC Public Health | Issue 1/2018

Login to get access

Abstract

The population-based Basque Colorectal Cancer (CRC) Screening Programme started in 2009 with a biennial immunochemical quantitative test (FIT) biennial and colonoscopy under sedation in positive cases. The population target of 586,700 residents was from 50 to 69 years old and the total coverage was reached at the beginning of 2014. The aim of our study was to determine possible scenarios in terms of incidence, mortality and reduction of Life-years-Lost (L-y-L) in the medium and long term of CRC.

Methods

Invitations were sent out by the Programme from 2009 to 2014, with combined organizational strategies. Simulation was done by MISCAN-colon (Microsimulation Screening Analysis) over 30 years comparing the results of screening vs no-screening, taking the population-based Cancer Registry into account. Lifetime population and real data from the Programme were used from 2008 to 2012. The model was run differentially for men and women.

Results

924,416 invitations were sent out from 2009 to 2014. The average participation rate was 68.4%, CRC detection rate was 3.4% and the Advanced Adenoma detection rate was 24.0‰, with differences observed in sex and age. Future scenarios showed a higher decrease of incidence (17.2% vs 14.7%), mortality (28.1% vs 22.4%) and L-y-L (22.6% vs 18.4%) in men than women in 2030.

Conclusions

The Basque Country CRC Programme results are aligned to its strategy and comparable to other programmes. MISCAN model was found to be a useful tool to predict the benefits of the programme in the future. The effectiveness of the Programme has not been formally established as case control studies are required to determine long term benefits from the screening strategy.
Literature
1.
2.
Departamento de Sanidad y Consumo. El cáncer en el País Vasco: incidencia, Mortalidad, Supervivencia y evolución temporal. Servicio Central de Publicaciones del Gobierno Vasco. Octubre 2010. 126 pg.
3.
Costantini AS, Martini A, Puliti D, Ciatto S, Castiglioni G, Grazzini G, et al. Colorectal cancer mortality in two areas of Tuscany with different screening exposures. J Natl Cancer Inst. 2008;100:1818–21.CrossRefPubMed
4.
Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004;126:1674–80.CrossRefPubMed
5.
Libby G, Brewster DH, McClements PL, Carey FA, Black RJ, Birrel J, et al. The impact of population-based faecal occult blood test screening on colorectal cancer mortality: a matched cohort study. Br J Cancer. 2012;107(2):255–9.CrossRefPubMedPubMedCentral
6.
van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH et l. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82–90.
7.
Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JC, et al. Screening for colorectal cancer: randomized trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010;59(1):62–8.CrossRefPubMed
8.
Levi Z, Birkenfeld S, Vilkin A, Bar-Chana M, Lifshitz I, Chared M, et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer. 2011;128(10):2415–24.CrossRefPubMed
9.
Segnan N, Patnick J, von Karsa L. (Eds). European guidelines for quality assurance in colorectal cancer screening and diagnosis. 1st edn. Luxembourg: Publications Office of the European Union, 2010. 386 pg.
10.
Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S, et al. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut. 2015;64:784–90.CrossRefPubMed
11.
Council of the European Union. Council Recommendation of 2 December 2003 on cancer screening (2003/878/EC). Off J Eur Union. 2003;(L 327):34–8.
12.
Ministerio de Sanidad y Consumo. The National Health System Cancer Strategy. Madrid, 2006. Madrid, Spain: Ministerio de Sanidad y Consumo; 2006.
13.
Ministerio de Sanidad y Consumo. The National Health System Cancer Strategy. Madrid, Update 2009. Madrid, Spain: Ministerio de Sanidad y Consumo; 2009.
14.
Portillo I, Idígoras I, Ojembarrena E, Arana-Arri E, Zubero MB, Pijoán JL, et al. Main results of the colorectal cancer screening program in the Basque Country (Spain). Gac Sanit. 2013;27(4):358–61.CrossRefPubMed
15.
Portillo I, Idigoras I, Ojembarrena E, Arana-Arri E, Hurtado JL, Basurco R, et al. Lesions detected in a colorectal cancer screening program in the Basque Country: first round (2009-2011). Gastroenterol Hepatol. 2013;36(5):301–8.CrossRefPubMed
16.
Loeve F, Boer R, van Ballegooijen M, et al. Final report MISCANCOLON microsimulation model for colorectal cancer: report to the National Cancer Institute project NO. NO1-CN55186. Rotterdam, The Netherlands: Department of Public health, Erasmus University; 1998.
17.
Salas D, Portillo I, Espinás JA, Ibáñez J, Vanaclocha M, Pérez-Riquelme F, et al. Implementation of colorrectal cancer screening in Spain: main results 2006-2011. Eur J Cancer Prev. 2017;26(1):17–26.CrossRef
18.
van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, Jansen JB, Verbeek AL, Dekker E. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer. 2009;101(8):1274–81.CrossRefPubMedPubMedCentral
19.
Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, Birkenfeld S, Leshno M, Niv Y. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007;146(4):244–55.CrossRefPubMed
20.
AJCC Cancer Staging Manual. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL et al. (Eds.) 7th ed. 2010, XV, 649 pg.
21.
Loeve F, Boer R, van Oortmarssen GJ, van Badegooigen M, Habbema JD. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res. 1999;32(1):13–33.CrossRefPubMed
22.
23.
Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer. 1975;36(6):2251–70.CrossRefPubMed
24.
Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, et al. COLONPREV study investigators. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366(8):697–706.CrossRefPubMed
25.
Rutter CM, Knudsen AB, Marsh TL, Doria-Rose VP, Johnson E, Pabiniak C, et al. Validation of models used to inform colorectal cancer screening guidelines: accuracy and implications. Med Decis Mak. 2016;36(5):604–14.CrossRef
26.
27.
Arminski TC, MClean DW. Incidence and distribution of adenomatous polyps of the colon and rectum based on 1,000 autopsy examinations. Dis Colon rectum. 1964;7:249–61.CrossRefPubMed
28.
Clark JC, Collan Y, Eide TJ, Estève J, Ewen S, Gibbs NM, et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer. 1985;36(2):179–86.CrossRefPubMed
29.
McGregor E, Hilsden RJ, Li FXL, Bryant HE, Murray A. Low uptake of colorrectal cancer screening 3 yr alterf relase of National Recommendations for screening. A J Gastroenterol. 2007;102(8):1727–35.CrossRef
30.
Tinmouth J, Ritvo P, McGregor SE, Patel J, Guglietti C, Levitt CA, et al. Colon cancer check primary care invitation pilot project: patients perceptions. Can Fam Physician. 2013;59(12):e541–9.PubMedPubMedCentral
31.
Van Roosbroek S, Hoeck S, van Hal G. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies. Cancer Epidemiol. 2012;36(5):e317–24.CrossRef
32.
Von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, European Colorectal Cancer Screening Guidelines Working Group. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy. 2013;45:51–9.CrossRef
33.
Van Rossum LGM, van Rijn AF, Laheij RJF, van Oijen MGH, Fockens P, Jansen JB, et al. Cutoff value determines the performance of a semiquantitative immunochemical faecal occult blood test in colorectal screening programme. Br J Cancer. 2009;101:1274–81.CrossRefPubMedPubMedCentral
34.
Denters MJ, Deutekom M, Bossuyt PM, Stroobants AK, Fockens P, Dekker E. Lower risk of advanced neoplasia among patients with a previous negative result from a faecal test for colorectal cancer. Gastroenterology. 2012;142(3):497–504.CrossRefPubMed
35.
Anttila A, Lönnberg S, Ponti A, Suonio E, Villain P, Coebergh JW, et al. Towards better implementation of cancer screening in Europe through improved monitoring and evaluation and greater engagement of cancer registries. Eur J Cancer. 2015;51(2):241–51.CrossRefPubMed
36.
Ferlay J, Shin HS, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010. 127(12):2893–917.
37.
38.
Ventura L, Mantellini P, Grazzini G, Castiglioni G, Buzzoni C, Rubeca T, et al. The impact of immunochemical faecal occult blood testing on colorectal cancer incidence. Dig Liver Dis. 2014;46(1):82–6.CrossRefPubMed
39.
Parente F, Vailati C, Boemo C, Bonoldi E, Ardizzola A, Ilardo A, et al. Improved 5-year survival of patients with immunochemical faecal blood test-screen-detected colorectal cancer versus non-screening cancers in northern Italy. Dig Liver Dis. 2015;47(1):68–72.CrossRefPubMed
40.
van Hees F, Zauber AG, van Veldhuizen H, Heijnen MLA, Penning C, de Koning HJ, et al. The value of models in informing resource allocation in colorectal cancer screening: the case of The Netherlands. Gut. 2015;64(12):1985–97.CrossRefPubMedPubMedCentral
41.
Klabunde C, Blom J, Bulliard J-L, Garcia M, Hagoel L, Mai V, et al. Participation rates for organized colorectal cancer screening programmes: an international comparison. J Med Screen. 2015;22(3):119–26.CrossRefPubMed
42.
Senore C, Inadomi J, Segnan N, Bellisario C, Hassan C. Optimising colorectal cancer screening acceptance: a review. Gut. 2015;64(7):1158–77.CrossRefPubMed
43.
Segnan N, Patnick J, von Karsa L. (Eds). European guidelines for quality assurance in colorectal cancer screening and diagnosis. 1st edn. Luxembourg: Publications Office of the European Union, 2010. 277 pg.
44.
Van der Meulen MP, Lansdorp-Vogelaar I, van Heijningen EMB, Kuipers EJ, van Ballegooijen M. Nonbleeding adenomas: evidence of systematic false-negative fecal immunochemical test results and their implications for screening effectiveness-a modeling study. Cancer. 2016;122(11):1680–8.CrossRefPubMed
45.
Metadata
Title
Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model
Authors
I. Idigoras
A. Arrospide
I. Portillo
E. Arana-Arri
L. Martínez-Indart
J. Mar
H. J. de Koning
R. Lastra
M. Soto-Gordoa
M. van der Meulen
I. Lansdorp-Vogelaar
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2018
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-017-4639-3

Other articles of this Issue 1/2018

BMC Public Health 1/2018 Go to the issue

Research article

Popularity and impact of using smart devices in medicine: experiences in Saudi Arabia

Research article

Health literacy in a population-based sample of Australian women: a cross-sectional profile of the Geelong Osteoporosis Study

Study protocol

Proactive expert system intervention to prevent or quit at-risk alcohol use (PRINT): study protocol of a randomized controlled trial

Research article

Assessing air quality index awareness and use in Mexico City

Research article

The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study

Correction

Correction to: Complex multiple risk intervention to promote healthy behaviours in people between 45 to 75 years attended in primary health care (EIRA study): study protocol for a hybrid trial